ETF Home ETF List Shorted Stocks Home About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for PTCT

Stock NamePTC Therapeutics Inc
TickerPTCT(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS69366J2006
LEI549300UJLWOIWFDGB318

Show aggregate PTCT holdings

News associated with PTCT

Bank of America Issues Pessimistic Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price objective reduced by Bank of America from $82.00 to $76.00 in a research report released on Wednesday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Several other brokerages have also issued reports on PTCT. Wall Street Zen lowered PTC Therapeutics from a […] - 2025-08-21 04:58:55
PTC Therapeutics (NASDAQ:PTCT) Price Target Lowered to $73.00 at Wells Fargo & Company
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price objective trimmed by Wells Fargo & Company from $79.00 to $73.00 in a research report released on Wednesday morning,Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company’s stock. Other equities analysts also recently issued reports about the company. Cantor Fitzgerald increased their […] - 2025-08-21 04:58:48
Noteworthy Monday Option Activity: ADBE, PTCT, RUM
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Adobe Inc (Symbol: ADBE), where a total of 32,627 contracts have traded so far, representing approximately 3.3 million underlying shares. That amounts to about 95.9% of - 2025-08-11 16:29:24
Natixis Advisors LLC Boosts Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Natixis Advisors LLC increased its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 26.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,220 shares of the biopharmaceutical company’s stock after buying an additional 3,160 shares during the quarter. Natixis […] - 2025-08-11 05:47:02
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of “Moderate Buy” by Brokerages
Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have given a hold rating, nine have issued a buy […] - 2025-08-11 05:11:00
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $80.00
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price target lifted by UBS Group from $71.00 to $80.00 in a research note released on Tuesday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. PTCT has been the topic of several other reports. Citigroup increased their target price on shares of PTC […] - 2025-08-01 05:49:00
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $120.00
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price objective lifted by Cantor Fitzgerald from $112.00 to $120.00 in a research note issued to investors on Tuesday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for PTC Therapeutics’ FY2025 earnings at $8.16 EPS and FY2026 earnings […] - 2025-08-01 05:48:59
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Y Intercept Hong Kong Ltd
Y Intercept Hong Kong Ltd lowered its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 54.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,981 shares of the biopharmaceutical company’s stock after selling 6,043 shares during the quarter. Y Intercept Hong […] - 2025-07-31 04:39:00
Truist Financial Issues Positive Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price objective increased by Truist Financial from $80.00 to $86.00 in a report published on Tuesday morning,Benzinga reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock. PTCT has been the topic of a number of other research reports. Wells Fargo & Company lifted […] - 2025-07-30 05:06:48
Bank of America Forecasts Strong Price Appreciation for PTC Therapeutics (NASDAQ:PTCT) Stock
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price target increased by Bank of America from $68.00 to $84.00 in a research report released on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities analysts have also weighed in on the company. Royal Bank […] - 2025-07-30 04:22:59
Barclays Forecasts Strong Price Appreciation for PTC Therapeutics (NASDAQ:PTCT) Stock
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price objective upped by Barclays from $42.00 to $46.00 in a report published on Tuesday,Benzinga reports. The brokerage currently has an equal weight rating on the biopharmaceutical company’s stock. Several other analysts also recently commented on PTCT. Robert W. Baird lowered their price objective on PTC Therapeutics […] - 2025-07-30 04:22:55
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up After Analyst Upgrade
PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s stock price gapped up prior to trading on Tuesday after Truist Financial raised their price target on the stock from $80.00 to $86.00. The stock had previously closed at $44.34, but opened at $47.50. Truist Financial currently has a buy rating on the stock. PTC Therapeutics shares […] - 2025-07-30 02:35:02
New York State Common Retirement Fund Buys 2,000 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)
New York State Common Retirement Fund boosted its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 8.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,421 shares of the biopharmaceutical company’s stock after acquiring an additional 2,000 shares […] - 2025-07-25 05:44:49
Cerity Partners LLC Acquires Shares of 12,581 PTC Therapeutics, Inc. (NASDAQ:PTCT)
Cerity Partners LLC bought a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 12,581 shares of the biopharmaceutical company’s stock, valued at approximately $641,000. A number of other institutional investors have […] - 2025-07-25 04:50:54
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of “Moderate Buy” by Brokerages
PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) has earned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, nine have assigned a buy recommendation and one […] - 2025-07-22 03:29:02
PTC Therapeutics, Inc. (NASDAQ:PTCT) Holdings Cut by Bank of New York Mellon Corp
Bank of New York Mellon Corp lowered its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 0.2% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 216,443 shares of the biopharmaceutical company’s stock after selling 439 shares during the period. […] - 2025-07-21 04:26:50
PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Position Decreased by Teacher Retirement System of Texas
Teacher Retirement System of Texas decreased its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 8.9% during the first quarter, HoldingsChannel.com reports. The fund owned 18,681 shares of the biopharmaceutical company’s stock after selling 1,830 shares during the period. Teacher Retirement System of Texas’ holdings in PTC Therapeutics were worth $952,000 […] - 2025-07-15 04:24:39
10,287 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Purchased by Allspring Global Investments Holdings LLC
Allspring Global Investments Holdings LLC bought a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) during the first quarter, HoldingsChannel reports. The institutional investor bought 10,287 shares of the biopharmaceutical company’s stock, valued at approximately $524,000. A number of other hedge funds have also recently bought and sold shares of PTCT. […] - 2025-07-11 04:31:12
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by Diversified Trust Co
Diversified Trust Co boosted its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 2.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,147 shares of the biopharmaceutical company’s stock after buying an additional 329 shares during the period. […] - 2025-06-30 05:10:54
PTC Therapeutics (NASDAQ:PTCT) Coverage Initiated at Truist Financial
Equities researchers at Truist Financial started coverage on shares of PTC Therapeutics (NASDAQ:PTCT – Get Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat.com reports. The firm set a “buy” rating and a $80.00 price target on the biopharmaceutical company’s stock. Truist Financial’s target price points to a potential upside […] - 2025-06-19 02:42:49
Pallas Capital Advisors LLC Makes New $353,000 Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Pallas Capital Advisors LLC purchased a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,925 shares of the biopharmaceutical company’s stock, valued at approximately $353,000. Several other institutional […] - 2025-06-13 05:38:53
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by GAMMA Investing LLC
GAMMA Investing LLC lifted its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 9,393.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 48,514 shares of the biopharmaceutical company’s stock after acquiring an additional 48,003 shares during the quarter. GAMMA Investing LLC’s holdings […] - 2025-06-13 04:36:51
Universal Beteiligungs und Servicegesellschaft mbH Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 108,345 shares of the biopharmaceutical company’s stock, valued at approximately $4,891,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.14% of PTC […] - 2025-06-02 06:10:57
Wells Fargo & Company Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $74.00
PTC Therapeutics (NASDAQ:PTCT – Get Free Report) had its price target hoisted by equities research analysts at Wells Fargo & Company from $68.00 to $74.00 in a report released on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price target suggests a potential upside of […] - 2025-05-29 02:31:00
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Recommendation of “Moderate Buy” by Brokerages
PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation, eight have assigned a buy recommendation and one has assigned a […] - 2025-05-28 04:46:51
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up After Earnings Beat
PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s share price gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $36.19, but opened at $39.40. PTC Therapeutics shares last traded at $39.92, with a volume of 455,281 shares trading hands. The biopharmaceutical company reported $10.04 […] - 2025-05-09 02:20:49
Analysts Set PTC Therapeutics, Inc. (NASDAQ:PTCT) PT at $63.92
Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) have earned an average rating of “Moderate Buy” from the fifteen brokerages that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have assigned a buy rating and one has […] - 2025-05-06 02:30:48
48,728 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Purchased by Raymond James Financial Inc.
Raymond James Financial Inc. acquired a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) during the fourth quarter, Holdings Channel reports. The firm acquired 48,728 shares of the biopharmaceutical company’s stock, valued at approximately $2,200,000. Several other institutional investors have also added to or reduced their stakes in the business. Smartleaf Asset Management […] - 2025-05-01 05:01:04
Federated Hermes Inc. Buys New Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Federated Hermes Inc. purchased a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 47,828 shares of the biopharmaceutical company’s stock, valued at approximately $2,159,000. A number of other hedge funds and other institutional investors have also recently modified their holdings of […] - 2025-04-14 05:15:06
PTC Therapeutics, Inc. (NASDAQ:PTCT) Position Reduced by Prudential Financial Inc.
Prudential Financial Inc. trimmed its position in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 5.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 5,620 shares of the biopharmaceutical company’s stock after selling 330 shares during the quarter. Prudential Financial Inc.’s holdings in PTC Therapeutics were worth $254,000 at the end of the most […] - 2025-04-11 05:03:01

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) PTCT holdings

DateNumber of PTCT Shares HeldBase Market Value of PTCT SharesLocal Market Value of PTCT SharesChange in PTCT Shares HeldChange in PTCT Base ValueCurrent Price per PTCT Share HeldPrevious Price per PTCT Share Held
2025-12-24 (Wednesday)53,425USD 4,186,917PTCT holding increased by 35794USD 4,186,9170USD 35,794 USD 78.37 USD 77.7
2025-12-23 (Tuesday)53,425PTCT holding decreased by -1500USD 4,151,123PTCT holding decreased by -182460USD 4,151,123-1,500USD -182,460 USD 77.7 USD 78.9
2025-12-22 (Monday)54,925USD 4,333,583PTCT holding increased by 18126USD 4,333,5830USD 18,126 USD 78.9 USD 78.57
2025-12-19 (Friday)54,925PTCT holding decreased by -3877USD 4,315,457PTCT holding decreased by -70584USD 4,315,457-3,877USD -70,584 USD 78.57 USD 74.59
2025-12-18 (Thursday)58,802USD 4,386,041PTCT holding decreased by -20581USD 4,386,0410USD -20,581 USD 74.59 USD 74.94
2025-12-17 (Wednesday)58,802PTCT holding decreased by -670USD 4,406,622PTCT holding decreased by -78756USD 4,406,622-670USD -78,756 USD 74.94 USD 75.42
2025-12-16 (Tuesday)59,472PTCT holding decreased by -134USD 4,485,378PTCT holding decreased by -59580USD 4,485,378-134USD -59,580 USD 75.42 USD 76.25
2025-12-15 (Monday)59,606PTCT holding increased by 268USD 4,544,958PTCT holding increased by 56632USD 4,544,958268USD 56,632 USD 76.25 USD 75.64
2025-12-12 (Friday)59,338USD 4,488,326PTCT holding increased by 11867USD 4,488,3260USD 11,867 USD 75.64 USD 75.44
2025-12-11 (Thursday)59,338PTCT holding increased by 982USD 4,476,459PTCT holding increased by 152279USD 4,476,459982USD 152,279 USD 75.44 USD 74.1
2025-12-10 (Wednesday)58,356USD 4,324,180PTCT holding increased by 36765USD 4,324,1800USD 36,765 USD 74.1 USD 73.47
2025-12-09 (Tuesday)58,356USD 4,287,415PTCT holding decreased by -200745USD 4,287,4150USD -200,745 USD 73.47 USD 76.91
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of PTCT by Blackrock for IE00BYXG2H39

Show aggregate share trades of PTCT

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-12-23SELL-1,50079.46077.260 77.480USD -116,220 54.07 Loss of -35,117 on sale
2025-12-19SELL-3,87779.31074.570 75.044USD -290,946 53.85 Loss of -82,159 on sale
2025-12-17SELL-67076.17074.185 74.383USD -49,837 53.67 Loss of -13,880 on sale
2025-12-16SELL-13476.13574.170 74.366USD -9,965 53.57 Loss of -2,787 on sale
2025-12-15BUY26877.38075.135 75.360USD 20,196 53.47
2025-12-11BUY98275.98073.960 74.162USD 72,827 53.27
2025-12-04BUY2,64079.03074.830 75.250USD 198,660 52.75
2025-12-02BUY1,98080.51077.865 78.129USD 154,696 52.52
2025-11-28BUY13286.76084.820 85.014USD 11,222 52.24
2025-11-26BUY39687.50082.840 83.306USD 32,989 51.92
2025-11-26BUY39687.50082.840 83.306USD 32,989 51.92
2025-11-25BUY66085.61581.890 82.262USD 54,293 51.77
2025-11-24BUY13281.16078.970 79.189USD 10,453 51.64
2025-11-20SELL-52878.74075.895 76.179USD -40,223 51.39 Loss of -13,091 on sale
2025-11-19BUY13276.88575.520 75.656USD 9,987 51.27
2025-11-18BUY79277.45574.020 74.363USD 58,896 51.14
2025-11-17BUY26477.43074.700 74.973USD 19,793 51.02
2025-11-14BUY13276.80074.085 74.356USD 9,815 50.90
2025-11-12BUY13275.00073.010 73.209USD 9,664 50.67
2025-11-10BUY13272.61070.540 70.747USD 9,339 50.44
2025-11-06BUY13273.98071.360 71.622USD 9,454 50.22
2025-11-04BUY13268.80066.215 66.473USD 8,775 50.02
2025-10-30BUY66069.88067.140 67.414USD 44,493 49.74
2025-10-29BUY26467.35068.140 68.061USD 17,968 49.64
2025-10-22SELL-52866.52067.580 67.474USD -35,626 49.18 Loss of -9,659 on sale
2025-10-20BUY26468.36068.630 68.603USD 18,111 48.98
2025-10-17BUY66065.95066.935 66.836USD 44,112 48.89
2025-10-15BUY1,05668.51069.260 69.185USD 73,059 48.78
2025-10-03BUY91765.37067.400 67.197USD 61,620 48.59
2025-10-02BUY13163.02063.330 63.299USD 8,292 48.51
2025-09-30BUY26261.37061.680 61.649USD 16,152 48.36
2025-09-26BUY26258.99059.130 59.116USD 15,488 48.23
2025-09-25BUY26257.84060.135 59.905USD 15,695 48.17
2025-09-24SELL-2,25459.50060.950 60.805USD -137,054 48.11 Loss of -28,618 on sale
2025-09-18BUY13762.88063.190 63.159USD 8,653 48.02
2025-09-17BUY41160.65061.950 61.820USD 25,408 47.95
2025-08-20SELL-54848.85049.990 49.876USD -27,332 47.86 Loss of -1,105 on sale
2025-07-30BUY54850.94051.650 51.579USD 28,265 47.81
2025-07-17SELL-27448.53049.450 49.358USD -13,524 47.87 Loss of -409 on sale
2025-07-16BUY56148.14048.660 48.608USD 27,269 47.86
2025-07-11SELL-1,08848.55049.420 49.333USD -53,674 47.85 Loss of -1,615 on sale
2025-07-07BUY40847.98049.150 49.033USD 20,005 47.83
2025-07-02BUY7,48049.15049.565 49.523USD 370,436 47.81
2025-06-20BUY1,32950.20051.210 51.109USD 67,924 47.80
2025-06-11BUY26250.82052.070 51.945USD 13,610 47.63
2025-06-10BUY26251.74052.325 52.267USD 13,694 47.60
2025-06-04SELL-13151.13051.570 51.526USD -6,750 47.47 Loss of -531 on sale
2025-04-23BUY13149.95050.600 50.535USD 6,620 47.70
2025-04-10SELL-1,04840.29041.815 41.662USD -43,662 47.88 Profit of 6,515 on sale
2025-04-08SELL-13139.77045.030 44.504USD -5,830 48.03 Profit of 462 on sale
2025-04-07SELL-13142.82044.985 44.769USD -5,865 48.09 Profit of 435 on sale
2025-04-04SELL-65543.24046.160 45.868USD -30,044 48.15 Profit of 1,492 on sale
2025-04-01BUY1,14946.60051.430 50.947USD 58,538 48.16
2025-03-31SELL-38750.96052.890 52.697USD -20,394 48.13 Loss of -1,768 on sale
2025-03-21BUY2,50557.14057.340 57.320USD 143,587 47.53
2025-03-14SELL-1,93654.50055.650 55.535USD -107,516 46.93 Loss of -16,661 on sale
2025-03-07SELL-24252.59053.790 53.670USD -12,988 46.49 Loss of -1,738 on sale
2025-03-04SELL-12151.80052.750 52.655USD -6,371 46.22 Loss of -778 on sale
2025-02-25BUY24250.36050.580 50.558USD 12,235 45.73
2025-02-19SELL-12150.42551.460 51.356USD -6,214 45.40 Loss of -721 on sale
2025-02-13BUY36349.67049.980 49.949USD 18,131 44.98
2025-02-12BUY12148.93048.990 48.984USD 5,927 44.90
2025-02-11BUY48448.63549.650 49.549USD 23,981 44.83
2024-12-30SELL-4,04145.77045.950 45.932USD -185,611 43.68 Loss of -9,090 on sale
2024-11-18SELL-1,98039.23039.860 39.797USD -78,798 41.42 Profit of 3,214 on sale
2024-11-08SELL-13244.28046.550 46.323USD -6,115 40.99 Loss of -704 on sale
2024-10-21SELL-13238.44039.250 39.169USD -5,170 0.00 Loss of -5,170 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of PTCT

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19134,8970383,22335.2%
2025-09-18283,3490426,43866.4%
2025-09-171,027,79401,194,00886.1%
2025-09-16193,3750307,40362.9%
2025-09-15322,7199534,13960.4%
2025-09-12385,45374562,96568.5%
2025-09-11284,2840452,60662.8%
2025-09-10278,5554408,67368.2%
2025-09-09468,2780688,80568.0%
2025-09-08283,8270420,01767.6%
2025-09-05346,6620658,62852.6%
2025-09-04461,6161,570706,32765.4%
2025-09-03500,00450703,68571.1%
2025-09-02410,808361623,97565.8%
2025-08-29260,928500368,01170.9%
2025-08-28169,3760286,54559.1%
2025-08-27117,5570225,79352.1%
2025-08-26159,7560292,41254.6%
2025-08-25184,3883278,80266.1%
2025-08-22212,2920337,12163.0%
2025-08-21110,0900199,27855.2%
2025-08-20214,8640342,11162.8%
2025-08-19574,175771,073,50653.5%
2025-08-18264,556175600,47344.1%
2025-08-15276,2360451,33761.2%
2025-08-14261,1060447,80158.3%
2025-08-13429,1970681,30463.0%
2025-08-12174,7390313,20955.8%
2025-08-11186,8746,675467,51140.0%
2025-08-08428,3251,746852,88150.2%
2025-08-07147,599144300,02149.2%
2025-08-0682,60020193,16742.8%
2025-08-05182,572112369,25749.4%
2025-08-04134,4690278,38048.3%
2025-08-01173,4700295,78658.6%
2025-07-31371,85250836,67944.4%
2025-07-30349,32275666,75252.4%
2025-07-29539,0072581,083,83649.7%
2025-07-28238,8930371,80364.3%
2025-07-25273,7870463,68359.0%
2025-07-2495,24840211,84045.0%
2025-07-23117,8270221,68053.2%
2025-07-22199,7160323,57861.7%
2025-07-21108,8530162,43967.0%
2025-07-18122,0370172,36370.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy